Zenith Drugs Ltd

Zenith Drugs has shown significant growth over the past three years, with net sales increasing from 91.66 Cr in March 2022 to 131.62 Cr in March 2024, and operating profit rising from 7.85 Cr to 19.03 Cr. Despite negative cash flow from operations, the company has expanded its asset base and achieved strong profitability improvements.

As of 01-October, Zenith Drugs Ltd is seeing a price increase to 67.90, with a 1.95% rise today, but has a year-to-date decline of 15.97%. Despite increased trading activity, the stock's long-term performance is lagging behind the broader market.

As of 19-Sep, Zenith Drugs Ltd's stock price is at 64.45, down 1.07%, and has underperformed its sector. The stock has declined 20.24% year-to-date and 51.52% over the past year, indicating negative investor sentiment.

As of August 28, 2025, Zenith Drugs is considered overvalued with a valuation grade of expensive, reflected by its high PE ratio of 16.96 and underperformance in the market, showing a year-to-date return of -12.38% compared to the Sensex's 3.62%.

As of August 26, 2025, Zenith Drugs is fairly valued with a PE ratio of 16.51, an EV to EBITDA ratio of 9.83, and competitive positioning compared to peers, despite a year-to-date return of -14.67%.

As of August 26, 2025, Zenith Drugs is fairly valued with a PE Ratio of 16.42, competitive against peers like Sun Pharma and Divi's Lab, and despite a year-to-date decline of 14.67%, it presents a reasonable investment opportunity at a price of 68.95.

As of August 22, 2025, Zenith Drugs is considered overvalued with a valuation grade of expensive, reflected by a PE Ratio of 17.48 and underwhelming stock performance, despite being lower than some peers like Sun Pharma and Divi's Lab.

As of August 22, 2025, Zenith Drugs is considered overvalued with a PE ratio of 17.48 and an EV to EBITDA of 10.34, showing a slight improvement in valuation from very expensive to expensive, while its recent stock performance has outperformed the Sensex in the short term but declined year-to-date.

As of August 22, 2025, Zenith Drugs is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 17.48, an EV to EBITDA of 10.34, and a Price to Book Value of 2.01, while its year-to-date return of -9.65% underperforms the Sensex's 5.18%.

As of 22-Aug, Zenith Drugs Ltd's stock price is at 73.00, down 3.76%, with a significant drop in delivery volume and mixed momentum indicators. Despite a weekly gain of 13.53%, it has underperformed year-to-date, contrasting with the Sensex's 5.18% rise.

As of 21-Aug, Zenith Drugs Ltd is priced at 75.85 with no change, having increased by 17.96% over the past week but underperforming its sector today. Despite short-term gains and increased investor interest, the stock has a year-to-date decline of 6.13%, indicating longer-term challenges.

As of August 20, 2025, Zenith Drugs is considered very expensive and overvalued with a PE ratio of 18.17 and a low PEG ratio of 0.00, despite a recent stock price surge that outperformed the Sensex.

As of 20-Aug, Zenith Drugs Ltd is currently priced at 75.85, reflecting a recent increase of 8.75% and strong short-term performance, outperforming its sector. However, it remains down 6.13% year-to-date, indicating challenges despite the recent uptick.

As of 18-Aug, Zenith Drugs Ltd's stock price is declining at 62.95, down 2.1%, and has underperformed its sector significantly. Despite a rise in trading volume, the stock's continued drop over various timeframes indicates ongoing challenges and lack of investor confidence.

As of 14-Aug, Zenith Drugs Ltd is priced at 64.30, up 1.58%, but has underperformed its sector and the broader market significantly. Despite a recent increase in investor participation, the stock has declined 20.42% year-to-date, indicating ongoing challenges.

As of 13-Aug, Zenith Drugs Ltd is facing a decline in its stock price, currently at 63.30, reflecting a year-to-date drop of 21.66% and underperformance against its sector and the broader market. The stock is trading below all key moving averages, indicating a challenging environment for investors.

As of 12-Aug, Zenith Drugs Ltd's stock price is at 64.00, reflecting a decline of 1.54% and significant underperformance compared to its sector and the Sensex. The stock has shown negative returns over multiple periods and decreased investor participation, indicating ongoing challenges.

As of 08-Aug, Zenith Drugs Ltd's stock price is 63.85, down 3.26%, and has significantly underperformed its sector and the broader market. The stock has seen a 10.51% decline over the past month, reflecting negative investor sentiment and reduced participation.

As of 23rd July, Zenith Drugs Ltd has a market capitalization of 122.00 Cr, classifying it as a Micro Cap company. Recent financial data for Net Sales and Net Profit is unavailable, with Shareholder's Funds at 62.26 Cr and Total Assets at 134.97 Cr as of March 2024.